The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system and thus improving the lives of millions of patients worldwide.
EDITOR OF THE MONTH
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital.
Read More
Read More
EDITOR OF THE MONTH
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital.
Editor of the month
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.
PROF. DR. SVEN FRANCQUE
LATEST ARTICLES
NASH: bariatric surgery and major adverse liver and cardiovascular outcomes
In this retrospective cohort study of 1158 patients with biopsy-proven fibrotic NASH without cirrhosis, bariatric surgery was significantly associated with a lower risk of major adverse liver outcomes.
Latest Videos
Latest articles from PubMed
- Endoscopic Bariatric and Metabolic Therapies and Their Effects on Metabolic Syndrome and Non-alcoholic Fatty Liver Disease - A Systematic Review and Meta-Analysis
- Non-alcoholic Fatty Liver Disease: Current Global Burden
- Increased PD-L1 Restricts Liver Injury in Nonalcoholic Fatty Liver Disease
- VMP1 regulates hepatic lipoprotein secretion and NASH independent of autophagy
- Non-Alcoholic Fatty Liver Disease: Does This Metabolic Condition Have Brain Function Sequelae?
- Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease
- Updated upper limit of normal for serum alanine aminotransferase value in Vietnamese population
- From NAFLD to MAFLD: Not just a change in the name
sign up for our newsletter
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.
Subscribe to us and get new updates